Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201066 | 0.87 | CA14 (0.40) | CA14CA12CA1CA9 | |
| SCHEMBL13897101 | 0.80 | CA14 (0.33) | CA14 | |
| SCHEMBL25969918 | 0.80 | CA14 (0.54) | CA14CA12CA1CA9MMP1 | |
| SCHEMBL15083230 | 0.78 | CA14 (0.41) | CA14HDAC1HDAC2 | |
| SCHEMBL4677852 | 0.78 | CA14 (0.44) | CA14CA12CA1CA9MMP1 | |
| SCHEMBL8285770 | 0.76 | CA14 (0.51) | CA14CA12CA1CA9MMP1 | |
| SCHEMBL15083257 | 0.75 | CA14 (0.40) | CA14HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL14755630 | 0.75 | CA14 (0.54) | CA14CA12CA1CA9MMP1 | |
| SCHEMBL8021973 | 0.75 | CA14 (0.54) | CA14CA12CA1CA9MMP1 | |
| SCHEMBL15083136 | 0.75 | CA14 (0.35) | CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034959-B2 | Methods of treating cancer with an antibody-drug conjugate | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034959-B2 | Methods of treating cancer with an antibody-drug conjugate | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-7977465-B2 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977465-B2 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-RE41252-E1 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-RE41252-E1 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090209734-A1 | PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR | MEDAREX, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209734-A1 | PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR | MEDAREX, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | MEDAREX, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | MEDAREX, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7498302-B2 | Disulfide prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498302-B2 | Disulfide prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | PDIA5, CD38, DUT | CA14 159/4885CA12 271/4885CA1 473/4885 |
| US-20090209734-A1 | PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR | VIP, PIN1, PDF | CA14 1808/4885CA12 2158/4885CA1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.